Cingulate (CING) Competitors

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Anavex Life Sciences' return on equity of -32.73% beat Cingulate's return on equity.

Anavex Life Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market.

In the previous week, Anavex Life Sciences had 6 more articles in the media than Cingulate. MarketBeat recorded 7 mentions for Anavex Life Sciences and 1 mentions for Cingulate. Anavex Life Sciences' average media sentiment score of 0.62 beat Cingulate's score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Anavex Life Sciences presently has a consensus target price of $21.33, indicating a potential upside of 577.25%. Cingulate has a consensus target price of $27.33, indicating a potential upside of 457.82%. Given Anavex Life Sciences' higher possible upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Cingulate.

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sagimet Biosciences presently has a consensus price target of $25.57, suggesting a potential upside of 220.04%. Cingulate has a consensus price target of $27.33, suggesting a potential upside of 457.82%. Given Cingulate's higher possible upside, analysts clearly believe Cingulate is more favorable than Sagimet Biosciences.

Sagimet Biosciences has a beta of 3.37, suggesting that its stock price is 237% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

Sagimet Biosciences' return on equity of -37.57% beat Cingulate's return on equity.

In the previous week, Sagimet Biosciences had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Sagimet Biosciences and 1 mentions for Cingulate. Sagimet Biosciences' average media sentiment score of 0.17 beat Cingulate's score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Cingulate has lower revenue, but higher earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cingulate has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Cingulate's return on equity.

In the previous week, AC Immune had 4 more articles in the media than Cingulate. MarketBeat recorded 5 mentions for AC Immune and 1 mentions for Cingulate. AC Immune's average media sentiment score of 0.86 beat Cingulate's score of 0.00 indicating that AC Immune is being referred to more favorably in the media.

AC Immune presently has a consensus target price of $7.50, indicating a potential upside of 230.40%. Cingulate has a consensus target price of $27.33, indicating a potential upside of 457.82%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than AC Immune.

AC Immune has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market.

Cingulate has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cingulate has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Cingulate's return on equity.

Sol-Gel Technologies presently has a consensus price target of $197.50, suggesting a potential upside of 133.73%. Cingulate has a consensus price target of $27.33, suggesting a potential upside of 457.82%. Given Cingulate's higher probable upside, analysts plainly believe Cingulate is more favorable than Sol-Gel Technologies.

In the previous week, Cingulate had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Sol-Gel Technologies has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market.

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sol-Gel Technologies has higher revenue and earnings than Cingulate. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.